A vaccine has shown potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone surgery, according to a Phase I trial led by researchers at The University of Texas ...
Jan 9, 2024
0
117
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), ...
Dec 12, 2023
0
0
Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias ...
Dec 11, 2023
0
0
The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results ...
Dec 11, 2023
0
0
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens—a major indicator of clinical improvement—compared with standard-of-care ruxolitinib monotherapy ...
Dec 11, 2023
0
0
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor-positive ...
Dec 6, 2023
0
1
Incorporating navy beans into the diet of colorectal cancer (CRC) survivors has the potential to positively impact both gut and host health by modulating markers linked to obesity and disease, according to new research from ...
Nov 30, 2023
8
247
A new Phase Ib/II study from researchers at The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center found that combining sensitizing drugs with a specific form of radiation therapy may be more effective ...
Nov 28, 2023
0
0
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further ...
Oct 23, 2023
0
0
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses and overall survival compared to standard chemotherapy for patients with metastatic urothelial cancers with FGFR ...
Oct 23, 2023
0
0
